Compare Abeona Therapeutics Inc (ABEO) vs Global X NASDAQ 100 Covered Call ETF (QYLD) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Global X NASDAQ 100 Covered Call ETF — how do they compare? Abeona Therapeutics Inc trades at $6.76 (market cap $373.32M), while Global X NASDAQ 100 Covered Call ETF trades at $18.09. Which is the better fit depends on your goals.
| ABEO | QYLD | |
|---|---|---|
Market Cap | $373.32M | — |
Sector | Health | Income / Options Overlay |
52-Week High | $7.23 | $18.52 |
52-Week Low | $4.17 | $16.46 |
Enterprise Value | $228.22M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
QYLD trades at $18.34, up 1.38% with a bullish technical signal driven by moving averages, though oscillators remain neutral. The ETF's covered-call strategy generates high monthly dividends, with recent payouts of $0.19 and $0.18, but long-term performance has lagged the Nasdaq-100's growth. News highlights concerns over NAV erosion despite the 12% yield.
Outlook: High income appeals to retirees, but capital appreciation is limited by the covered-call structure. Risks include underperformance in bull markets and concentration in tech. Investors prioritize yield over growth, yet must monitor erosion risks highlighted by financial media.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Global X NASDAQ 100 Covered Call ETF
QYLD is an ETF that follows a covered call strategy on the NASDAQ 100 Index. The fund holds a long position in the stocks of the NASDAQ 100 and simultaneously writes (sells) call options on the index. The primary goal is to generate monthly income from the option premiums. This strategy can reduce portfolio volatility and provide income, but it limits potential capital appreciation from a significant rise in the NASDAQ 100 Index.
Read more on QYLD →
